Registry for patients treated with electroporation for cancer
Electroporation for Cancer Treatment Real World Registry
This study is collecting information from cancer patients who have received a new treatment using electroporation with chemotherapy or calcium to see how well it works and what side effects it may cause.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Mirai Medical Industry-sponsored |
| Locations | 1 site (London) |
| Trial ID | NCT04929912 on ClinicalTrials.gov |
What this trial studies
This registry collects data on long-term disease outcomes for patients who have undergone treatment with reversible electroporation combined with chemotherapy or calcium. It focuses on evaluating tumor response rates, recurrence rates, and characterizing side effects and adverse events related to the treatment. The observational nature of the study allows for real-world insights into the effectiveness and safety of this innovative approach to cancer treatment.
Who should consider this trial
Good fit: Ideal candidates include patients who have been treated with calcium electroporation or electrochemotherapy and are capable of providing informed consent.
Not a fit: Patients who have not undergone calcium electroporation or electrochemotherapy will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into the effectiveness and safety of electroporation treatments for cancer, potentially leading to improved patient outcomes.
How similar studies have performed: While the approach of using electroporation in cancer treatment is gaining interest, this registry aims to provide real-world data, making it a novel contribution to the existing body of knowledge.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient who has been treated using Calcium Electroporation * Any patient who has been treated using Electrochemotherapy * Patients must be mentally capable of understanding the information given * Patients must give written informed consent. Exclusion Criteria: * None
Where this trial is running
London
- Royal London Hospital — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Sean H Kinsella
- Email: sean@mirai-medical.com
- Phone: +353 91 442 498
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.